Atara (ATRA) news
Recent news
Atara Bio 2Q loss/share 32c vs. EPS 19c y/y
Atara Biotherapeutics (NASDAQ: ATRA) reported a net loss of $0.32 per share for the second quarter of 2025, compared to net income of $0.19 per share in the same period of 2024. The company’s financial performance reflects a significant shift from profitability to a loss, driven primarily by the…
AInvest Wire · Aug 12, 2026US FDA puts clinical hold on Atara's trials for cancer cell therapies
US FDA puts clinical hold on Atara's trials for cancer cell therapies The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Atara Biotherapeutics, a leading biotechnology company specializing in T-cell immunotherapy, regarding the Biologics License Application…
AInvest Wire · Jan 21, 2025ImportantAtara Biotherapeutics shares up 20% premarket after Co. announces board appointment and capital raise
Atara Biotherapeutics shares up 20% premarket after Co. announces board appointment and capital raise Atara Biotherapeutics, Inc. (ATRA) experienced a significant surge in its stock price by 20% during pre-market hours on October 3, 2024. The biotechnology company announced a board appointment and…
AInvest Wire · Sep 4, 2024Atara Biotherapeutics submits Tabelecleucel Blac in Epstein-Barr.
Atara Biotherapeutics submits Tabelecleucel Blac in Epstein-Barr. The biopharmaceutical company Atara Biotherapeutics, known for its T-cell immunotherapy expertise and innovative use of allogeneic Epstein-Barr virus (EBV) T-cells, has reported significant progress in its regulatory pathway for…
AInvest Wire · May 20, 2024Atara Biotherapeutics gets FDA clearance of IND for ATA3219.
Atara Biotherapeutics gets FDA clearance of IND for ATA3219. Atara Biotherapeutics, a leader in T-cell immunotherapy, has announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of ATA3219 as a monotherapy for the…
AInvest Wire · Feb 29, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.